Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.84 USD
+0.01 (0.55%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.82 -0.02 (-1.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 201 - 220 ( 315 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Going Straight to the DNA Mutation; Continuing to Leverage Columbia Relationship
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino Tracker - Week ending 4/24/2020 (AG a Positive)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY; Reports the Quarter with $153M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2019 Results; Multiple Upcoming Catalysts and Potential Major Cash Flow Events
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J